Economic evaluation of MF59 adjuvanted vaccine against influenza in the high-risk elderly population in France

Journal of Medical Economics

Volumn 7, Issue 1-4, 2004, Pages 1-18

  Piercy, James ^a   Ryan, James ^b   Megas, Francoise ^b  

^a ADELPHI REAL WORLD   (United Kingdom)

^b MAPI VALUES   (United States)

Author keywords

Cost effectiveness; Economic evaluation influenza vaccination; MF59 adjuvanted vaccination

Indexed keywords

EID: 33044504950     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200407001018     Document Type: Article

References (55)

1. World Health Organisation. Weekly Epidemiological Record 2000; 75: 281-288.
2. Public Health Laboratory Service. PHLS Surveillance of Influenza Activity Updates, 2000.
3. Sullivan KM. Health impact of influenza in the United States. Pharmacoeconomics 1996; 9 (Suppl. 3): 26-33. (Pubitemid 26308765)
4. Szucs T. The socio-economic burden of influenza. Journal of Antimicrobial Chemotherapy 1999; 44: B11-15.
5. Groupes Régionaux d'Observation de la Grippe (GROG) sentinel network.
6. GEIG. Groupe d'etude et d'Information sur la Grippe (GEIG) (Influenza Study and Information Group). L'impact médicoéconomique de la grippe (The medical and economic impact of influenza). Enquête. Rome: GEIG; 1998.
7. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. Journal of the American Medical Association 2003; 289: 179-186. (Pubitemid 36068705)
8. Barker WH, Mullooly JP. A study of excess mortality during influenza epidemics in the United States, 1968-1976. American Journal of Epidemiology 1982; 115: 479-480.
9. Hannoun C. The socioeconomics of influenza and influenza vaccination in Europe. Foreword. Pharmacoeconomics 1996; 9 (Suppl. 3). (Pubitemid 26321020)
10. CNAM DP. La grippe. Campagne d'information vaccinale anti-grippale. Dossier de Presse 1999-2000.
11. Faber C. Grippe: la couverture vaccinale des plus de 70 ans remonte. Le Quotidien du Médecin 1999; 6554: 34.
12. Wood SC, Nguyen VH, Schmidt C. Economic evaluations of influenza vaccinations in the elderly. Disease Management and Health Outcomes 2000; 8: 273-285.
13. Postma MJ, Bos JM, van Gennep M et al. Economic evaluation of influenza vaccination. Pharmacoeconomics 1999; 16 (Suppl. 1): 33-40.
14. Peter C, Fremont C. Incidence de la vaccination antigrippale sur les depenses de soins ambulatoires des personnes agees de 60 a 69 ans. Revue Medicale de l'Assurance Maladie 1996; 4 (Evaluation): 84-90.
15. Nordin J, Mullooly J, Poblete S et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. Journal of Infectious Diseases 2001; 184: 665-670. (Pubitemid 32826416)
16. Carrat F, Flahault A, Boussard E et al. Surveillance of influenza-like illness in France. The example of the 1995/1996 epidemic. Journal of Epidemiology and Community Health 1998; 52 (Suppl. 1): 32S-38S.
17. Dupuis M, McDonald DM, OH G. Distribution of adjuvant MF59 and antigen g DZ after intramuscular injection in mice. Vaccine 1999; 18: 434-439. (Pubitemid 29462599)
18. Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Archives of Internal Medicine 1998; 158: 1769-1776. (Pubitemid 28421420)
19. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on clinical evaluation of new vaccines. CPMP/EWP/463/97. European Agency for the Evaluation of Medicinal Products (EMEA), May 1999.
20. Couch RB, Kasel JA. Immunity to influenza in man. Annual Review of Microbiology 1983; 37: 529-549.
21. Fries LF, Dillon SB, Hildreth JE et al. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge. Journal of Infectious Diseases 1993; 167: 593-601. (Pubitemid 23056325)
22. Pyhala R, Aho K. Serum HI antibody and protection against influenza: a follow-up survey at community level of three epidemics caused by different H3N2 variants. International Journal of Epidemiology 1975; 4: 127-129.
23. Rytel MW, Jackson LJ, Niebojewski RA et al. New live attenuated influenza A/England/42/72 (H3N2) vaccine (Alice): reactogenicity, immunogenicity, and protection efficacy. Journal of Infectious Diseases 1975; 132: 652-659.
24. Hirota Y, Kaji M, lde S et al. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine 1997; 15: 962-967. (Pubitemid 27308571)
25. Belshe RB, Gruber NC, Mendelman PM et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. Journal of Infectious Diseases 2000; 181: 1133-1137. (Pubitemid 30194502)
26. Gasparini R, Pozzi T, Montomoli E et al. Increased immunogenicity of the MF59- adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. European Journal of Epidemiology 2001; 17:135-140. (Pubitemid 32900039)
27. Baldo V, Menegon T, Bonello C et al. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 2001 19: 3472-3475. (Pubitemid 32710298)
28. De Donato S, Geranoff D, Minutello M et al. Safety and immunogenicity of MF59- adjuvanted influenza vaccine in the elderly. Vaccine 1999; 17: 3094-3101. (Pubitemid 29366990)
29. Minutello M, Senatore F, Ceachinelli G et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999; 17: 99-104. (Pubitemid 28494106)
30. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001; 19: 2673-2680. (Pubitemid 32234288)
31. Piercy J, Megas F. The cost-effectiveness of M59 adjuvanted vaccination. Chiron SpA, Italy, data on file.
32. Weinstein MC, Fineberg HV. Clinical Decicion Analysis. Philadelphia, PA: WB Saunders; 1980.
33. Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 2002; 20: 2562-2578. (Pubitemid 34615597)
34. Drummond MF, O'Brien B, Stoddart GL et al. Methods for the Economic Evaluation of Health Care Programmes, 2nd edn. Oxford: Oxford Medical Publications; 1997.
35. Levy E. French economic evaluations of influenza and influenza vaccination. Pharmacoeconomics 1996; 9 (Suppl. 3): 62-66. (Pubitemid 26308771)
36. Nichol KL, Goodman M. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years. Pharmacoeconomics 1999; 16 (Suppl. 1): 63-71. (Pubitemid 29512634)
37. Helliwell BE, Drummond MF. The costs and benefits of preventing influenza in Ontario's elderly. Canadian Journal of Public Health 1998; 79: 175-180.
38. Mullooly JP, Bennett MD, Hornbrook MC et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Annals of Internal Medicine 1994; 121: 947-952. (Pubitemid 24370859)
39. Carrat F, Sahler C, Rogez S et al. Influenza burden of illness: estimates from a national prospective survey of household contacts in France. Archives of Internal Medicine 2002; 162: 1842-1848. (Pubitemid 35051695)
40. Scuffham P, Piercy J. Estimating influenzarelated excess hospital admissions. Value in Health 2001; 4: 428.
41. PMSI. Programme de Médicalisation des Systèmes d'Information (PMSI). Paris: Department of public and private hospitalisation statistics, 1999.
42. Nichol KL, Margolis KL, Wuorenma J et al. Effectiveness of influenza vaccine in the elderly. Gerontology 1996; 42: 274-279
43. Govaert TM, Sprenger MJ, Dinant GJ et al. Immune response to influenza vaccination of elderly people. A randomized doubleblind placebo-controlled trial. Vaccine 1994; 12: 1185-1189. (Pubitemid 24293238)
44. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. British Medical Bulletin 1979; 35: 69-75. (Pubitemid 9096975)
45. Collège des Economistes de la Santé (CES). Recommandations de Bonnes Pratiques des Méthodes d'Evaluation Economique des Stratégies Thérapeutiques. Lettre du College N. special, April 1997.
46. Benedict A, Hutton J. Efficient production of health benefits: cost-effectiveness evidence and utilisation of health technology in the UK. Value in Health 2002; 5: 449-450.
47. Bridges C, Thompson W, Meltzer M et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults. Journal of the American Medical Assocation 2000; 284: 1655-1663.
48. National Institute for Clinical Excellence. Guidance for Manufacturers and Sponsors: Technology Appraisals Process Series No 5; 2001.
49. Spackman M. Discount rates and rates of return in the public sector: economic issues. Working paper 113. Government Economic Service, 1991.
50. Collège des Economistes de la Santé. Guide methodologique pour ĺvaluation économique des stratégies de la santé. Juillet 2003.
51. Caisse Nationale d'Assurance Maladie DP (CNAM-DP) (French National Health Insurance-Press department). La grippe. Campagne d'information vaccinale anti-grippale (Influenza vaccination campaign). Paris: Dossier de Presse; 2000.
52. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. Journal of the American Medical Association 2003; 289: 179-186. (Pubitemid 36068705)
53. Banzhoff A, Nacci P, Podda A. A new MF59 adjuvanted influenza vaccinae enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003; 49: 177-184. (Pubitemid 36438758)
54. Ahmed AH, Nicholson KG, Nguyen-Van- Tam JS. Reduction in mortality associated with influenza vaccine during 1989-1990 epidemic. Lancet 1995; 346: 591-595.
55. Nichol K. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. New England Journal of Medicine 2003; 348: 1322-1332. (Pubitemid 36384099)